Thomas J. Galloway, MD
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Associate Professor, Department of Radiation Oncology
Chief, Division of Head and Neck Radiation Oncology
Medical Director, Clinical Research
TRDG Member, Head and Neck Cancer; Melanoma and Skin Cancer; Thyroid and Endocrine Cancer
Specialties
Treatment Focus
- Intensity modulated radiation therapy
- Stereotactic body radiation therapy
- Modulated electron beam therapy
- Interstitial brachytherapy
- Rotational arc therapy
Research Program
Key Awards
- ARRO Educator of the year, Fox Chase Cancer Center 2013
- Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013
Treatment Philosophy
I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.
Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.
I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity
Educational Background
- MD, University of Florida, Gainesville, FL, 2005
- BS, Chemistry, University of Florida, Gainesville, FL, 2001
Certifications
- American Board of Radiology
- Radiation Oncology
Memberships
- American Society of Therapeutic Radiology (ASTRO)
- Radiation Therapy Oncology Group (RTOG)
- Institutional Principal Investigator for Fox Chase Cancer Center (Institution 2212) July 2013 - Present
- American Radium Society (ARS)
- Radiological Society of North America (RSNA)
- American College of Radiology (ACR)
- Eastern Cooperative Oncology Group (ECOG)
Honors & Awards
- ARRO Educator of the year, Fox Chase Cancer Center 2013
- Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013
Tierra Ryan
Tierra Ryan
At 31, Tierra Ryan was a young professional woman, working as a pharmacist and a medical writer for a large pharmaceutical company, when she was shocked to learn she was diagnosed with Hodgkin's lymphoma. Fox Chase Cancer Center was one of two hospitals her doctor recommended. Tierra underwent chemotherapy and radiation therapy at Fox Chase, and in November 2014 was placed on surveillance because her cancer was in remission. Today, she still works in the pharmaceutical industry, but as a medical science liaison focusing on oncology. "I’m truly thankful to the doctors and staff at Fox Chase because they saved my life," Tierra said. "Because of them, I have a long life ahead of me."
Stephen Meier
Stephen Meier
"I’m the kind of person who isn’t prone to panic. Panic just causes confusion. So, when what began as soreness on the right side of my throat turned out to be cancer, I remained calm and figured somebody can fix it."
Paul Reitano
Paul Reitano
Paul Reitano was an active 45-year-old male with two careers, who was looking to start a family with his wife. After getting an initial diagnosis of squamous cell carcinoma from an ENT at a local hospital, Paul and his wife decided to seek a second opinion from Fox Chase Cancer Center. After Paul learned he actually had HPV tonsil cancer, not squamous cell carcinoma, he sought radiation therapy, chemotherapy, and surgery at Fox Chase with the help of Dr. Thomas Galloway. Today he is cancer free. "Not a day goes by since then that I am not grateful that I chose Fox Chase for my care," Paul said. "There was a real comfort in Fox Chase, I trusted them completely. The decision to be treated by Fox Chase saved my life and allowed me to give life to a little girl."
Richard Millham
Richard Millham
I was diagnosed with Merkel cell carcinoma, a highly aggressive and rare skin cancer, with only about 1,800 cases reported in the United States each year. The dermatologist recommended I seek treatment and a plastic surgeon right away. Fox Chase had a Merkel cell team, one of only about 15 in the country.
B. Mark Wilson
B. Mark Wilson
On May 6, 2014, B. Mark Wilson of Smyrna, Delaware, made a chance visit to Fox Chase Cancer Center. The 51-year-old came to accompany his father, George, for a follow-up visit. The elder Wilson had been treated for kidney cancer two years earlier. Mark, who had just been diagnosed with stage IV throat cancer, was just days away from his own surgery, and brought along his medical paperwork. “I was hoping for a second opinion,” he admitted. “Little did I know Fox Chase has a Rapid Access Program, which meant I could be seen immediately. And as a result, my treatment plan changed dramatically.”
Research Program
Research Interests
- Head and neck cancer
- Head and neck cancer survivorship
- Skin Cancer (both melanoma and non-melanoma)
- Merkel Cell Carcinoma Radiation target delineation
- Pre-treatment imaging evaluation beyond the diagnosis
- Impact of time to treatment in the curative management of head and neck cancer
Selected Publications
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed
Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed
Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA. Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation. Epub ahead of print in Head and Neck PubMed
Galloway TJ, Ridge JA. Management of squamous cancer metastatic to cervical nodes with unknown primary. Epub ahead of print in Journal of Clinical Oncology PubMed
Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed
Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867
Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7
Keller L, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango M, Burtness B, Mehra M, Ridge JA. p16 Status, Pathologic and Clinical Characteristics, Biomolecular Signature, and Long Term Outcomes in Unknown Primary Carcinomas of the Head and Neck. (Head and Neck 2014 36(12) 1677-1684
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder D, Ridge JA, Galloway TJ. Dysplasia at the Margin? Investigating the case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. (Oral Oncology 2013 49(11): 1083-1087)
Burtness B, Bauman J, Galloway T. Novel Targets in HPV-Negative Head and Neck Cancer – Overcoming Resistance to EGFR Inhibition. (Lancet Oncology 2013; 14(8): e302-9).
Lango M, Flieder D, Arrangoiz R, Yu M, Li T, Burtness B, Mehra R, Galloway T, Veloski C, Ridge JA. Effect of extranodal extension on biochemical endpoints, nodal persistence and systemic disease progression in metastatic papillary thyroid carcinoma. (Thyroid. 2013; 23(9): 1099-1105)
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral Neck Therapy in the Human Papillomavirus Era: Accepted Regional Spread Patterns. (Head and Neck. 2013; 35(2): 160-164)
Galloway TJ, Amdur RJ, Liu C, Yeung A, Mendenhall WM. Revisiting Unnecessary Larynx Irradiation with Whole Neck IMRT. (Practical Radiation Oncology. 2011 1, 27-32)
Galloway TJ, Morris CG, Mancuso AA, Amdur RJ, Mendenhall WM. Impact of Radiographic Findings on Prognosis for Skin Cancer with Clinical Perineural Invasion. Cancer. 2005 Mar 15; 103(6):1254-7 PubMed
Additional Publications
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Associate Professor, Department of Radiation Oncology
Chief, Division of Head and Neck Radiation Oncology
Medical Director, Clinical Research
TRDG Member, Head and Neck Cancer; Melanoma and Skin Cancer; Thyroid and Endocrine Cancer
Specialties
Treatment Focus
- Intensity modulated radiation therapy
- Stereotactic body radiation therapy
- Modulated electron beam therapy
- Interstitial brachytherapy
- Rotational arc therapy
Research Program
Key Awards
- ARRO Educator of the year, Fox Chase Cancer Center 2013
- Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013
Treatment Philosophy
I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.
Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.
I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity
Education
Educational Background
- MD, University of Florida, Gainesville, FL, 2005
- BS, Chemistry, University of Florida, Gainesville, FL, 2001
Certifications
- American Board of Radiology
- Radiation Oncology
Memberships
- American Society of Therapeutic Radiology (ASTRO)
- Radiation Therapy Oncology Group (RTOG)
- Institutional Principal Investigator for Fox Chase Cancer Center (Institution 2212) July 2013 - Present
- American Radium Society (ARS)
- Radiological Society of North America (RSNA)
- American College of Radiology (ACR)
- Eastern Cooperative Oncology Group (ECOG)
Honors & Awards
- ARRO Educator of the year, Fox Chase Cancer Center 2013
- Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013
Research Profile
Research Interests
- Head and neck cancer
- Head and neck cancer survivorship
- Skin Cancer (both melanoma and non-melanoma)
- Merkel Cell Carcinoma Radiation target delineation
- Pre-treatment imaging evaluation beyond the diagnosis
- Impact of time to treatment in the curative management of head and neck cancer
Publications
Selected Publications
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed
Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed
Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA. Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation. Epub ahead of print in Head and Neck PubMed
Galloway TJ, Ridge JA. Management of squamous cancer metastatic to cervical nodes with unknown primary. Epub ahead of print in Journal of Clinical Oncology PubMed
Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed
Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867
Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7
Keller L, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango M, Burtness B, Mehra M, Ridge JA. p16 Status, Pathologic and Clinical Characteristics, Biomolecular Signature, and Long Term Outcomes in Unknown Primary Carcinomas of the Head and Neck. (Head and Neck 2014 36(12) 1677-1684
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder D, Ridge JA, Galloway TJ. Dysplasia at the Margin? Investigating the case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. (Oral Oncology 2013 49(11): 1083-1087)
Burtness B, Bauman J, Galloway T. Novel Targets in HPV-Negative Head and Neck Cancer – Overcoming Resistance to EGFR Inhibition. (Lancet Oncology 2013; 14(8): e302-9).
Lango M, Flieder D, Arrangoiz R, Yu M, Li T, Burtness B, Mehra R, Galloway T, Veloski C, Ridge JA. Effect of extranodal extension on biochemical endpoints, nodal persistence and systemic disease progression in metastatic papillary thyroid carcinoma. (Thyroid. 2013; 23(9): 1099-1105)
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral Neck Therapy in the Human Papillomavirus Era: Accepted Regional Spread Patterns. (Head and Neck. 2013; 35(2): 160-164)
Galloway TJ, Amdur RJ, Liu C, Yeung A, Mendenhall WM. Revisiting Unnecessary Larynx Irradiation with Whole Neck IMRT. (Practical Radiation Oncology. 2011 1, 27-32)
Galloway TJ, Morris CG, Mancuso AA, Amdur RJ, Mendenhall WM. Impact of Radiographic Findings on Prognosis for Skin Cancer with Clinical Perineural Invasion. Cancer. 2005 Mar 15; 103(6):1254-7 PubMed
Additional Publications
Related Articles
26 PATIENT COMMENTS
-
5.0
September 20, 2019
excellent experience.in all respects
-
5.0
September 19, 2019
very professional, knowledgeable and friendly
-
5.0
August 28, 2019
Very happy with the care I received.
-
5.0
August 23, 2019
Dr. Galloway & his nurse [...] are the best.
-
5.0
August 19, 2019
Top notch care!
-
5.0
August 12, 2019
Excellent - as always.
-
5.0
August 06, 2019
Dr. Galloway saved my life.
-
5.0
July 29, 2019
excellent service and experience
-
5.0
July 28, 2019
I love Fox Chase and will continue to follow up with Dr Galloway and his staff
-
5.0
June 30, 2019
Very good - Excellent experience. From the day I had my treatment - always - very good making me feel better and improved -
-
5.0
June 24, 2019
Dr. Galloway is an awesome/person. He always treats me with interest and respect.
-
5.0
May 28, 2019
I had a very nice visit.
-
5.0
May 26, 2019
Fox Chase is wonderful.Dr Galloway, [...] have been great along with the entire nursing staff during my 3 1/2 years.
-
5.0
May 12, 2019
Dr. Galloway and his nurse [...] are the best. Very professional and genuinely care about their pts.
-
5.0
April 29, 2019
All good.
-
5.0
April 22, 2019
As always excellent visit.
-
5.0
April 09, 2019
No bad experiences everything was better than good.
-
5.0
March 18, 2019
Dr. Galloway is very good!
-
5.0
March 17, 2019
Great doctor.
-
5.0
March 13, 2019
Dr Galloway along with his assistant were so caring. They devoted so much time to answer all my questions. I didn't have the scans they needed with me and delivered them the following day. They reviewed them and sent me a response in 2 days. Very happy I decided to seek their advice as a second opinion.
LOAD MORE